Keryx Biopharmaceuticals (KERX)
Create an AlertKeryx Biopharmaceuticals News
Notable Analyst Rating Changes 06/19: (CX) (ADBE) (LINE) Upgraded; (CLF) (S) (BBRY) Downgraded
Street Insider 10:30 AMStreetInsider.com Pre-Open Movers 6/19: (PLX) (CYTK) (ADBE) Higher; (OSH) (VNDA) (TTEK) Lower (more...)
Street Insider 9:30 AMJPMorgan Starts Keryx Biopharmaceuticals (KERX) at Overweight
Street Insider 8:20 AMLitigation Settlements, Data Compliance Reviews, and Clinical Trials Pave Way for Solid Footing in Healthcare - Research Report on Pfizer, Merck, Bristol-Myers Squibb, Keryx and Pacira Pharmaceuticals
PR Newswire Jun 17NEW YORK, June 17, 2013 /PRNewswire/ -- Today, Wall Street Reports announced new research reports highlighting Pfizer Inc. (NYSE: PFE), Merck & Co. Inc. (NYSE: MRK), Bristol-Myers Squibb Company (NYSE: ...
Five Best-Performing Biotech Stocks of 2013 (Some May Surprise You)
Jun 11In a bubbly year for the biotech sector, these five stocks stand out over the rest.
Biotech Stock Mailbag: 2013 Clinical Trials Calendar
Jun 7Biotech columnist Adam Feuerstein answers readers' questions about healthcare companies.
Keryx (KERX) Will Present Updated Zerenex Phase 3 Data
Street Insider Jun 3Keryx Biopharmaceuticals, Inc. Announces Zerenex™ Phase 3 Data Presented at the 2013 World Congress of Nephrology
PR Newswire Jun 3NEW YORK, June 3, 2013 /PRNewswire/ -- Keryx Biopharmaceuticals, Inc. (Nasdaq: KERX) today announced the presentation of updated efficacy and safety data from the Phase 3 long-term clinical trial of Zerenex ...
Commit To Buy Keryx Biopharmaceuticals At $5, Earn 26%
May 31Investors considering a purchase of Keryx Biopharmaceuticals Inc. shares, but tentative about paying the going market price of $8.14/share, might benefit from considering selling puts among the alternative strategies at their disposal.
Recent Quotes
| Symbol | Price | Chg | Chg % | Market Cap |
|---|---|---|---|---|
| KERX | 8.24 | +0.58 | +7.57% | 673.36M |
